Inhibition of PTPRE suppresses tumor progression and improves sorafenib response in hepatocellular carcinoma

被引：3
|
作者：
Dong, Renshun [1 ,2 ,3 ]
Wang, Tianci [1 ,2 ,3 ]
Dong, Wei [1 ,2 ,3 ,4 ,5 ,6 ]
Zhu, He [1 ,2 ,3 ,4 ,5 ,6 ]
Liu, Qiumeng [1 ,2 ,3 ,4 ,5 ]
Liang, Huifang [1 ,2 ,3 ,4 ,5 ,6 ]
Chen, Xiaoping [1 ,2 ,3 ,4 ,5 ,6 ]
Zhang, Bixiang [1 ,2 ,3 ,4 ,5 ,6 ]
Zhang, Xuewu [1 ,2 ,3 ,4 ,5 ,6 ]
机构：
[1] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hepat Surg Ctr, Wuhan 430030, Hubei, Peoples R China
[2] Hubei Key Lab Hepatopancreato Biliary Dis, Wuhan 430030, Hubei, Peoples R China
[3] Hubei Prov Clin Med Res Ctr Hepat Surg, Wuhan 430030, Hubei, Peoples R China
[4] Minist Educ, Key Lab Organ Transplantat, Wuhan 430030, Hubei, Peoples R China
[5] Chinese Acad Med Sci, NHC Key Lab Organ Transplantat, Wuhan 430030, Hubei, Peoples R China
[6] Chinese Acad Med Sci, Key Lab Organ Transplantat, Wuhan 430030, Hubei, Peoples R China
来源：
BIOMEDICINE & PHARMACOTHERAPY | 2024年 / 173卷
基金：
中国国家自然科学基金;
关键词：
PTPRE inhibitor; Hepatocellular carcinoma; Sorafenib; Organoid; OPEN-LABEL; PLUS; ATEZOLIZUMAB; BEVACIZUMAB; METABOLISM; MYC;
D O I：
10.1016/j.biopha.2024.116366
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Hepatocellular carcinoma (HCC) has a poor prognosis, and the efficacy of current therapeutic strategies is extremely limited in advanced diseases. Our previous study reported that protein tyrosine phosphatase receptor epsilon (PTPRE) is a promoting factor in HCC progression. In this study, our objective was to evaluate the treatment effect of PTPRE inhibitors in different HCC preclinical models. Our results indicated that the PTPRE inhibitory compound 63 (Cpd-63) inhibited tumor cell proliferation, migration, and HCC organoid growth. Mechanism research revealed that Cpd-63 could inhibit the expression of MYC and MYC targets by inhibiting the activation of SRC. Additionally, we found that Cpd-63 could improve the response of sorafenib in HCC cells. In conclusion, we demonstrated that the PTPRE inhibitors represented a potential therapeutic agent for HCC management.
引用
收藏
页数：11
相关论文
共 50 条
  • [21] Survival of Hepatocellular Carcinoma Patients Treated with Sorafenib beyond Progression
    Apostolidis, Leonidas
    Pfeiffenberger, Jan
    Gotthardt, Daniel
    Radeleff, Boris
    Mehrabi, Arianeb
    Schemmer, Peter
    Jaeger, Dirk
    Schirmacher, Peter
    Stremmel, Wolfgang
    Schulze-Bergkamen, Henning
    Springfeld, Christoph
    Weiss, Karl Heinz
    GASTROINTESTINAL TUMORS, 2018, 5 (1-2) : 38 - 46
  • [22] Predictors of time to progression in patients treated with sorafenib for hepatocellular carcinoma
    Salimi, S.
    Mudaliar, S.
    Davison, S.
    Shackel, N.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 : 92 - 93
  • [23] MiR-22 regulates HIF-1A pathway and tumor progression and represents a possible biomarker of sorafenib response in hepatocellular carcinoma
    Galvani, G.
    Leoni, I.
    Monti, E.
    Vianello, C.
    Marinelli, S.
    Marisi, G.
    Gardini, A. Casadei
    Foschi, G. F.
    Giovannini, C.
    Baldassarre, M.
    Ravaioli, M.
    Cescon, M.
    Vasuri, F.
    Domenicali, M.
    Negrini, M.
    Piscaglia, F.
    Stefanelli, C.
    Gramantieri, L.
    Fornari, F.
    DIGESTIVE AND LIVER DISEASE, 2024, 56 : S96 - S97
  • [24] Tmem39b promotes tumor progression and sorafenib resistance by inhibiting ferroptosis in hepatocellular carcinoma
    Zhuang, Ming
    Zhang, Xue
    Wen, Liming
    Qin, Jiamin
    ONCOLOGY RESEARCH, 2024, 32 (08) : 1347 - 1357
  • [25] Glutaryl-CoA dehydrogenase suppresses tumor progression and shapes an anti-tumor microenvironment in hepatocellular carcinoma
    Lao, Yuanxiang
    Cui, Xiaohan
    Xu, Zhu
    Yan, Hongyao
    Zhang, Zechuan
    Zhang, Zhenwei
    Geng, Longpo
    Li, Binghua
    Lu, Yijun
    Guan, Qifei
    Pu, Xiaohong
    Zhao, Suwen
    Zhu, Jiapeng
    Qin, Xihu
    Sun, Beicheng
    JOURNAL OF HEPATOLOGY, 2024, 81 (05)
  • [26] Genomic characteristics of hepatocellular carcinoma patients with response to sorafenib
    Yim, Sun Young
    Kang, Sang-Hee
    Lee, Young-Sun
    Lee, Yoonseok
    Lim, Ji-Hwan
    Kim, Tae Hyung
    Jung, Young Kul
    Seo, Yeon Seok
    Yim, Hyung Joon
    Yeon, Jong Eun
    Lee, Ju-Seog
    Kim, Ji Hoon
    JOURNAL OF HEPATOLOGY, 2023, 78 : S578 - S578
  • [27] GENOMIC CHARACTERISTICS OF HEPATOCELLULAR CARCINOMA PATIENTS WITH RESPONSE TO SORAFENIB
    Young, Yim Sun
    Kim, Ji Hoon
    Yim, Hyung Joon
    Seo, Yeon Seok
    Yeon, Jong Eun
    Lee, Young-Sun
    Kim, Taehyung
    Kang, Seong Hee
    Lee, Yoonseok
    Kim, Jong Su
    Jung, Chang Hee
    HEPATOLOGY, 2023, 78 : S2132 - S2133
  • [28] Complete response to sorafenib in a patient with recurrent hepatocellular carcinoma
    Huan, Hong-Bo
    Lau, Wan-Yee
    Xia, Feng
    Ma, Kuan-Sheng
    Bie, Ping
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (39) : 14505 - 14509
  • [29] Differential Response to Sorafenib Administration for Advanced Hepatocellular Carcinoma
    Huang, Song-Fong
    Chong, Sio-Wai
    Huang, Chun-Wei
    Hsu, Heng-Yuan
    Pan, Kuang-Tse
    Hung, Chien-Fu
    Wu, Tsung-Han
    Lee, Chao-Wei
    Hsieh, Chia-Hsun
    Wang, Ching-Ting
    Chai, Pei-Mei
    Yu, Ming-Chin
    BIOMEDICINES, 2022, 10 (09)
  • [30] Frizzled-4 expression enhances hepatocellular carcinoma progression, sorafenib resistance and suppresses anti-tumor CD8 T cell immunity
    Luo, Jie
    Gong, Lanqi
    Yang, Yuma
    Liu, Qin
    Huang, Jiao
    Fang, Xiaona
    Guan, Xin-Yuan
    CANCER RESEARCH, 2023, 83 (07)
12345